Five psychedelic biotech companies are advancing toward Phase 3 trials for treating depression and anxiety disorders. Helus Pharma reported positive Phase 2a results for SPL026 in major depressive disorder published in Nature Medicine. AtaiBeckley, Definium Therapeutics, GH Research, and LB Pharmaceuticals are all progressing late-stage clinical programs with multiple Phase 3 readouts expected in 2026, signaling the sector's maturation toward regulatory approval.

U.S. stock futures rose on Monday as major indices opened the first full trading week of 2026 higher. Following the U.S. strike on Venezuela and removal of President Maduro, crude oil prices fluctuated around $57.29 per barrel. Several stocks gained attention: Vertiv Holdings jumped on an upgrade, GH Research soared on FDA update news, Nukkleus rose after acquiring Israeli defense software, Ironwood advanced on positive FY26 guidance, and Brand Engagement Network climbed on a new vendor agreement. JPMorgan's outlook suggests continued but challenged strength in U.S. equities, with potential 10-15% corrections offset by year-end gains driven by AI-related spending.

GH Research announced presentation of long-term clinical data on GH001, a potential treatment for treatment-resistant depression, at the 38th Annual European College of Neuropsychopharmacology Congress in Amsterdam.

GH Research submitted a complete response to FDA's clinical hold on GH001, with one remaining issue regarding respiratory tract histology in rats. The Phase 2b trial showed a 73% remission rate at 6 months for treatment-resistant depression, with no serious adverse events and promising treatment outcomes.

GH Research PLC, a clinical-stage biopharmaceutical company, announced the submission of its complete response to the FDA regarding the clinical hold on its Investigational New Drug Application for GH001, its lead product candidate for treating treatment-resistant depression.

GH Research PLC reported positive results from a Phase 2b trial of its lead product candidate GH001 in patients with treatment-resistant depression, meeting the primary endpoint with a significant placebo-adjusted reduction in depression scores. The company also provided updates on its financial position and ongoing clinical development activities.

The report provides an in-depth analysis of the Postpartum Depression (PPD) pipeline, showcasing insights into more than ten diverse companies and over ten pipeline drugs. It highlights innovative therapeutic candidates, including RE-104 by Reunion Neuroscience and GH001 by GH Research, and their potential impact on PPD treatment paradigms.

GH Research PLC reported positive results from its Phase 2b clinical trial of GH001 in patients with treatment-resistant depression, with the primary endpoint met and a majority of patients achieving remission. The company also provided updates on its Phase 1 trial for a proprietary aerosol delivery device and its response to the IND hold on GH001. The company's cash position remains strong, with additional funding received from a public offering.

The depression treatment market is experiencing steady growth, driven by rising mental health awareness, increasing prevalence of depression, and advancements in novel therapies. The market is expanding with the introduction of innovative antidepressants, psychedelic-based treatments, and digital therapeutics.

GH Research PLC, a clinical-stage biopharmaceutical company, announced the pricing of its $150 million public offering of 10,000,000 ordinary shares at $15.00 per share. The company is developing a novel treatment for treatment-resistant depression.

GH Research PLC, a clinical-stage biopharmaceutical company, reported financial results for Q3 2024 and provided updates on its lead product candidate GH001 for treatment-resistant depression. The company also has ongoing trials for GH002 and GH003, and is addressing a clinical hold on its IND for GH001.

GH Research (GHRS) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.